
We Claim:


1. A compound of formula



(I)

or a tautomer, ~~prodrug,~~ N-oxide, pharmaceutically acceptable ester or pharmaceutically acceptable salt thereof, wherein

Ring Hy represents




;

optionally substituted with R''';

R^1 and R^2 are the same or different and are independently selected from CH_3, CH_2F, CHF_2, CF_3, substituted or unsubstituted $C_{(3-5)}$cycloalkyl, CH_2-OR^a, CH_2-NR^aR^b, ~~CN~~ and COOH with the proviso that;

Ring Ar represents:



;

T is independently selected from CR^a or N and each of U, V and W is independently selected from CH, CR^a, or N, wherein each occurrence of R^a is the same or different and is independently selected from nitro, hydroxy, cyano, halogen, -OR^c, -$S(=O)_q$-R^c, –C(=Y)-R^c, -CR^cR^d-C(=Y)-R^c, -CR^cR^d-Y-CR^cR^d-,-C(=Y)-NR^cR^d-, -NRR^d-C(=Y)-NR^cR^d-, -$S(=O)_q$-NR^cR^d-, -NR^cR^d-$S(=O)_q$-NR^cR^d-, -NR^cR^d-NR^cR^d-, substituted or unsubstituted alkyl,

substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocylyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroarylalkyl;

~~T, U, V and W are the same or different and are independently selected from CR^a and N;~~

Z^1, Z^2 and Z^3 are the same or different and are independently selected from CR^a, CR^aR^b, O, S and $-NR^a$, with the proviso that at least one of Z^1, Z^2 and Z^3 represents O, S or $-NR^a$;

L_1 and L_2 together represent –NH-C(=X)-, –NH-$S(=O)_q$-, -C(=X)NH-, or ~~$-S(=O)_qNH-$ or~~ –NH-CR'R''- ;

A is absent or selected from –(CR'R'')-, O, $S(=O)_q$, C(=X) and $-NR^a$;

atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which are the same or different and are selected from O, NH and S;

each occurrence of Y is selected from O, S and $-NR^a$; and

each occurrence of q independently represents 0, 1 or 2;

wherein the term substituted refers to a substitution selected from hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (=0), thio(=S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, $-COOR^x$, $-C(0)R^x$, $-C(S)R^X$, $-C(O)ONR^xR^y$, $-NR^yR^z$, $-NR^xCONR^yR^z$, $-N(R^x)SOR^y$, $-N(R^x)S0_2R^y$, $-(=N-N(R^x)R^y)$, $-NR^X C(0)OR^y$, $-NR^xR^y$, $-NR^xC(0)R^y-$, $-R^xC(S)R^y$ $-NR^xC(S)NR^yR^z$, $-SONR^xR^y-$, $-S0_2 NR^xR^y-$, $-OR^x$, $-OR^xC(0)NR^yR^z$, $-OR^xC(0)OR^y-$, $-OC(0)R^x$, $-OC(0)NR^xR^y$, $-R^xNR^yC(0)R^z$, $-R^xOR^y$, $-R^xC(0)OR^y$, $-R^xC(0)NR^yR^z$, $-R^xC(0)R^x$, $-R^xOC(0)R^y$, $-SR^X$, $-SOR^x$, $-S0_2R^x$, and $-ON0_2$, wherein R^x, R^y and R^z in each of the above groups can be hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted heterocyclylalkyl ring, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring, or any two of R^x, R^y and R^z may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include heteroatoms which may be same or different and are selected from O, NR^X or S wherein the substituents in the aforementioned "substituted" groups cannot be further substituted;

with the proviso that

i)

a) both R^1 and R^2 at the same time do not represent CF_3,

b) both R^1 and R^2 at the same time do not represent CH_3,

c) when R^1 is CF_3 then R^2 is not CH_3 and

d) when R^1 is CH_3 then R^2 is not CF_3;

~~e) when ring Ar is 1-4 phenyl, L_1 and L_2 together represent –NH-C(=O)- or -C(=O)NH- and R^1 is CF_3 then R^2 is not CH_2F, CHF_2, CF_3, CN, COOH or $COOR^a$;~~

~~f) when ring Ar is 1-4 phenyl, L_1 and L_2 together represent –NH-C(=O)- or -C(=O)NH- and R^2 is CF_3 then R^1 is not CH_2F, CHF_2, CF_3, CN, COOH or $COOR^a$;~~

e) ~~g)~~ when ring Ar is thiophene or furan, L_1 and L_2 together represent –NH-C(=O)- or -C(=O)NH and R^1 is CF_3 then R^2 is not ~~CN,~~ COOH or $COOR^a$;

f) ~~h)~~ when ring Ar is thiophene or furan, L_1 and L_2 together represent –NH-C(=O)- or -C(=O)NH and R^2 is CF_3 then R^1 is not ~~CN,~~ COOH or $COOR^a$; and

ii) the compound of formula (I) does not include:

N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-(difluoromethyl)-5-methyl-1H-Pyrazole-3-carboxamide;

N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-1-methyl-4-nitro-1H-Pyrazole-5-carboxamide;

N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(1-ethyl-5-methyl-1H-pyrazol-4-yl)-5-Isoxazolecarboxamide;

N-[4-[5-cyclopropyl-3-trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4,5-dihydro-3-(2-methoxyphenyl)- 5-Isoxazole carboxamide;

N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-[4-(1,1-dimethylethyl)phenyl] -cyclopropanecarboxamide;

N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-Pyridine carboxamide;

N-[4-[3-cyclopropyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-Pyridine carboxamide;


N-benzyl-6-(3,5-dicyclopropyl-1H-pyrazol-1-yl) pyridazin-3-amine;

(6-(3-cyano-1-methylpyrazol-4-yl)-2-{[2-(3-fluorophenyl)ethyl] amino} (3-pyridyl))-N-(3- pyridylmethyl)carboxamide;


carboxylate; or

methyl 1-(2-acetamido-4-(4-chlorophenylcarbamoyl)phenyl)-5-methyl-1H-pyrazole-3-carboxylate.


2. A compound of claim 1, wherein Hy is selected from




3. A compound of claim <u>1</u> ~~2~~, wherein Hy is




4. A compound of claim 3, wherein Hy is



5. A compound of claim 1, wherein Ar is



6. A compound of claim 6, wherein Ar is




7. A compound of claim 1, wherein L_1 and L_2 together represent -NH-C(=O)-, ~~-NH-S(=O)$_q$-~~, -C(=O)NH- or –NH-CH_2-.

8. A compound of claim 7, wherein L_1 and L_2 together represent -NH-C(=O)-, –C(=O)NH- or ~~S(=O)$_q$NH-~~ -NH-CH_2-.


9. A compound of claim 1, wherein A is absent or is selected from -(CR'R")- or -NR^a

10. A compound of claim 9, wherein A is –CH_2- or –CHMe- , –(CR'R")-, where R' and R" are joined to form a substituted or unsubstituted saturated or unsaturated 3-6 membered ring, which may optionally include one or more heteroatoms which are the same or different and are selected from O, NR^a and S;


11. A compound of claim 9 or 10, wherein A is

-NH- , -CH_2- , -CHMe- ,  or 

12. A compound of claim 1, wherein Cy is



15. A compound of formula (IA)



(IA)

or a tautomer, ~~prodrug,~~ N-oxide, pharmaceutically acceptable ester, or pharmaceutically acceptable salt thereof, wherein

R^1 and R^2 are the same or different and are independently selected from CH_3, CH_2F, CHF_2, CF_3, substituted or unsubstituted $C_{(3-5)}$ cycloalkyl, CH_2-OR^a, CH_2-NR^aR^b, ~~CN~~ and COOH with the proviso that;

T is independently selected from CR^a or N and each of U, V and W is independently selected from CH, CR^a or N, wherein each occurrence of R^a is the same or different and are independently selected from nitro, hydroxy, cyano, halogen, -OR^c, -$S(=O)_q$-R^c, –C(=Y)-R^c, -CR^cR^d-C(=Y)-R^c, -CR^cR^d-Y-CR^cR^d-,-C(=Y)-NR^cR^d-, -C(=Y)-NR^cR^d-, -$S(=O)_q$-NR^cR^d-, -NR^cR^d-$S(=O)_q$-NR^cR^d-, -NR^cR^d-NR^cR^d-, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl;

~~T, U, V and W are the same or different and are independently selected from CR^a and N;~~

L_1 and L_2 together represent –NH-C(=X)-, –NH-$S(=O)_q$-, -C(=X)NH-, or ~~-$S(=O)_q$NH-~~ or –NH-CR'R"-;

A is absent or selected from –(CR'R'')-, O, $S(=O)_q$, C(=X) and $-NR^a$;

each occurrence of R' and R'' are the same or different and are independently selected from hydrogen, hydroxy, cyano, halogen, $-OR^a$, $-COOR^a$, $-S(=O)_q-R^a$, $-NR^aR^b$, $-C(=X)-R^a$, substituted or unsubstituted $C_{(1-6)}$ alkyl group, substituted or unsubstituted $C_{(1-6)}$ alkenyl, substituted or unsubstituted $C_{(1-6)}$ alkynyl, and substituted or unsubstituted $C_{(3-5)}$cycloalkyl, or R' and R'' may be joined to form a substituted or unsubstituted saturated or unsaturated 3-6 membered ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR^a and S;

R''' is selected from hydrogen, hydroxy, cyano, halogen, $-OR^a$, $-COOR^a$, $-S(=O)_q-R^a$, $-NR^aR^b$, $-C(=X)-R^a$, substituted or unsubstituted $C_{(1-6)}$ alkyl group, substituted or unsubstituted $C_{(1-6)}$ alkenyl, substituted or unsubstituted $C_{(1-6)}$ alkynyl, and substituted or unsubstituted $C_{(3-5)}$cycloalkyl;

each occurrence of X is independently selected from O, S and -NR^a;

Cy is selected from monocyclic substituted or unsubstituted cycloalkyl group, monocyclic substituted or unsubstituted heterocyclyl, monocyclic substituted or unsubstituted aryl, and monocyclic substituted or unsubstituted heteroaryl;

each occurrence of R^a and R^b are the same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, -OR^c, -$S(=O)_q$-R^c, -NR^cR^d, –C(=Y)-R^c, -CR^cR^d-C(=Y)-R^c, -CR^cR^d-Y-CR^cR^d-,-C(=Y)-NR^cR^d-, -NRR^d-C(=Y)-NR^cR^d-, -$S(=O)_q$-NR^cR^d-, -NR^cR^d-$S(=O)_q$-NR^cR^d-, -NR^cR^d-NR^cR^d-, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocylyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroarylalkyl, or when R^a and R^b substitutent are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR^c and S;

each occurrence of R^c and R^d may be same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, or when two R^c and/or R^d substitutents are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which are the same or different and are selected from O, NH and S;

each occurrence of Y is selected from O, S and -NR^a; and

each occurrence of q independently represents 0, 1 or 2,

wherein the term substituted refers to a substitution selected from hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (=0), thio(=S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, -$COOR^x$, -$C(0)R^x$, -$C(S)R^X$, -$C(O)ONR^xR^y$, -NR^yR^z, -$NR^xCONR^yR^z$, -$N(R^x)SOR^y$, -$N(R^x)S0_2R^y$, -(=N-$N(R^x)R^y$), -NR^X $C(0)OR^y$, -NR^xR^y, -$NR^xC(0)R^y$-, - $R^xC(S)R^y$ -$NR^xC(S)NR^yR^z$, -$SONR^xR^y$-, -$S0_2$ NR^xR^y-, -OR^x, -$OR^xC(0)NR^yR^z$, -$OR^xC(0)OR^y$-, -$OC(0)R^x$, -$OC(0)NR^xR^y$, - $R^xNR^yC(0)R^z$, -R^xOR^y, -$R^xC(0)OR^y$, -$R^xC(0)NR^yR^z$, -$R^xC(0)R^x$, -$R^xOC(0)R^y$, -SR^X, -SOR^x, -$S0_2R^x$, and -$ON0_2$, wherein R^x, R^y and R^z in each of the above

groups can be hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted heterocyclylalkyl ring, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring, or any two of R^x, R^y and R^z may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include heteroatoms which may be same or different and are selected from O, NR^X or S wherein the substituents in the aforementioned "substituted" groups cannot be further substituted;

with the proviso that

i)

a) both R^1 and R^2 at the same time do not represent CF_3,

b) both R^1 and R^2 at the same time do not represent CH_3,

c) when R^1 is CF_3 then R^2 is not CH_3 and

d) when R^1 is CH_3 then R^2 is not CF_3; and

~~e) when ring Ar is 1-4 phenyl, L_1 and L_2 together represent NH-C(=O)- or -C(=O)NH- and R^1 is CF_3 then R^2 is not CH_2F, CHF_2, CF_3, CN, COOH or $COOR^a$;~~

~~f) when ring Ar is 1-4 phenyl, L_1 and L_2 together represent NH-C(=O)- or -C(=O)NH- and R^2 is CF_3 then R^1 is not CH_2F, CHF_2, CF_3, CN, COOH or $COOR^a$;~~

ii) the compound of formula (I) does not include N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-(difluoromethyl)-5-methyl-1H-Pyrazole-3-carboxamide; N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-1-methyl-4-nitro-1H-Pyrazole-5-carboxamide; N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(1-ethyl-5-methyl-1H-pyrazol-4-yl)-5-Isoxazolecarboxamide; N-[4-[5-cyclopropyl-3-trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4,5-dihydro-3-(2-methoxyphenyl)- 5-Isoxazole carboxamide; N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-[4-(1,1-dimethylethyl)phenyl] - Cyclopropanecarboxamide; N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-3-Pyridinecarboxamide;N-[4-[3-cyclopropyl-5-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]- 3-Pyridine carboxamide; N-benzyl-6-(3,5-dicyclopropyl-1H-pyrazol-1-yl) pyridazin-3-amine;

(6-(3-cyano-1-methylpyrazol-4-yl)-2-{[2-(3-fluorophenyl)ethyl]amino}(3-pyridyl))-N-(3-pyridylmethyl)carboxamide;

1-{3-Chloro-5-[4-(2-fluoro-3-trifluoromethyl-phenyl)-thiazol-2-ylcarbamoyl]-pyridin-2-yl}-5-methyl-1 H-pyrazole-3-carboxylic acid;

N1-(4-(1-(difluoromethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-2-methylphenyl)-3-iodo-N2-(2-methyl-1-(methylthio)propan-2-yl)phthalamide; N1-(4-(1-(difluoromethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-2-methylphenyl)-3-iodo-N2-(2-methyl-1-(methylsulfinyl)propan-2-yl)phthalamide; N1-(4-(1-(difluoromethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-2-methylphenyl)-3-iodo-N2-(2-methyl-1-(methylsulfonyl)propan-2-yl)phthalamide; N1-(4-(1-(difluoromethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-2-methylphenyl)-3-iodo-N2-(1-(methylthio)propan-2-yl)phthalamide; N1-(4-(1-(difluoromethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-2-methylphenyl)-3-iodo-N2-(1-(methylsulfinyl)propan-2-yl)phthalamide; N1-(4-(1-(difluoromethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-2-methylphenyl)-3-iodo-N2-(1-(methylsulfonyl)propan-2-yl)phthalamide; (2R,4R)-4-methoxy-pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-{[2-fluoro-4-(5-methoxymethyl-3-methyl-pyrazol-1-yl)phenyl]amide}; (2R,4R)-4-methoxy-pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-{[2-fluoro-4-(3-methoxymethyl-5-methyl-pyrazol-1-yl)phenyl]amide};

4-Amino-3-(4-((5-(4-cyano-1-methyl-5-methylthio-1H-pyrazol-3-yl) thiophene-2-sulfonyl) amino) phenyl) furo[2, 3-d] pyrimidine;
5- (4-Cyano-l-methyl-5-methylsulfanyl-l-H-pyrazol-3-yl)-thiophene-2-sulfonic acid [((R)-1-methyl-pyrrolidin-3-yloxy)-trifluoromethyl-phenyl]-amide;
ethyl 1-(4-(4-chlorobenzamido)phenyl)-5-methyl-1H-pyrazole-3-carboxylate; 4-chloro-N-(4-(5-((dimethyl amino)methyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)benzamide; 4-chloro-N-(4-(5-(hydroxylmethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)benzamide; N-(4-(5-(tert-butoxymethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-4-chlorobenzamide; 4-chloro-N-(4-(5-(methoxymethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)benzamide; N-(4-(5-(methoxymethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)nicotinamide; 4-chloro-N-(4-(3-(methoxymethyl)-5-methyl-1H-pyrazol-1-yl) phenyl)benzamide; 4-chloro-N-(4-(3-(methoxymethyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl) phenyl)benzamide; N-(4-(3-(methoxymethyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl) phenyl)nicotinamide; N-(4-(3-cyclopentyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)nicotinamide;
ethyl 1-(2-acetamido-4-(4-chlorophenylcarbamoyl)phenyl)-5-methyl-1H-pyrazole-3-carboxylate; ethyl 1-(2-amino-4-(4-chlorophenylcarbamoyl)phenyl)-5-methyl-1H-pyrazole-3-carboxylate; ethyl 1-(4-(4-chlorophenylcarbamoyl)-2-nitrophenyl)-3-methyl-1H-pyrazole-5-carboxylate; ethyl 1-(4-(4-chlorophenylcarbamoyl)-2-nitrophenyl)-5-methyl-1H-pyrazole-3-carboxylate; or methyl 1-(2-acetamido-4-(4-chlorophenylcarbamoyl)phenyl)-5-methyl-1H-pyrazole-3-carboxylate.

16. A compound of claim 15, wherein

L_1 and L_2 together represent –NH-C(O)-; and

Cy is selected from monocyclic substituted or unsubstituted aryl, and monocyclic substituted or unsubstituted heteroaryl.

17. A compound of any of claims 15-16, wherein both R^1 and R^2 represent cyclopropyl.

18. A compound of any of claims 15-16, wherein one of R^1 and R^2 is CF_3 and the other is independently cyclopropyl, CH_2F or CHF_2.

~~19. A compound of any of claims 15-16, wherein T, U, V, and W are independently CH, CF or N.~~

~~20. A compound of claim 19, wherein T is CF or N and each of U, V and W is CH.~~


~~21. A compound of claim 19, wherein each of T and V is independently CF or N and each of U and W is CH.~~

2219. A compound of claim 15, wherein L_1 and L_2 together represent –NH-C(=O)-, –NH-S(=O)$_q$-, -C(=O)NH- or –NH-CH_2-;


2023. A compound of any of claims 15-16, wherein A is absent, -NH-, or –CH_2-.

2124. A compound of claim 2023, wherein A is –CH_2-.


2225 A compound of claim 15, wherein Cy is selected from



23.26 A compound of claim 15 or 16, wherein Cy is



2427. A compound of formula



(IA-III)

or a tautomer, ~~prodrug,~~ N-oxide, pharmaceutically acceptable ester, or pharmaceutically acceptable salt thereof, wherein

R^1 and R^2 are the same or different and are independently selected from CH_2F, CHF_2, CF_3, cyclopropyl with the proviso that both R^1 and R^2 at the same time do not represent CF_3;

~~T and V are the same or different and are independently selected from CH, CF and N; with the proviso that at least one of T or V is CF or N;~~

~~each of U and V is CR^a;~~

T is independently selected from CF or N and each of U, V and W is independently selected from CH, CF or N;

L_1 and L_2 together represent –NH-C(=X)-, –NH-$S(=O)_q$-, -C(=X)NH-, or ~~-$S(=O)_q$NH-~~ or –NH-CR'R''-;

A is absent or selected from –(CR'R'')- and -NR^a;

each occurrence of R' and R'' are the same or different and are independently selected from hydrogen or substituted or unsubstituted $C_{(1-6)}$ alkyl group or R' and R'' may be joined to form a substituted or unsubstituted saturated or unsaturated 3-6 membered ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR^a and S;

R''' is selected from hydrogen, or halogen

each occurrence of X is independently selected from O, S and -NR^a;

Cy is selected from monocyclic substituted or unsubstituted heterocyclyl, monocyclic substituted or unsubstituted aryl, and monocyclic substituted or unsubstituted heteroaryl;

each occurrence of R^a and R^b are the same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, -OR^c, -$S(=O)_q$-R^c, -NR^cR^d, –C(=Y)-R^c, -CR^cR^d-C(=Y)-R^c, -CR^cR^d-Y-CR^cR^d-,-C(=Y)-NR^cR^d-, -NRR^d-C(=Y)-NR^cR^d-, -$S(=O)_q$-NR^cR^d-, -NR^cR^d-$S(=O)_q$-NR^cR^d-, -NR^cR^d-NR^cR^d-, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or

unsubstituted cycloalkenyl, substituted or unsubstituted heterocylyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted

arylalkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroarylalkyl, or when R^a and R^b substitutent are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR^c and S;

each occurrence of R^c and R^d may be same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, or when two R^c and/or R^d substitutents are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which are the same or different and are selected from O, NH and S;

each occurrence of Y is selected from O, S and $-NR^a$; and

each occurrence of q independently represents 0, 1 or 2,

wherein the term substituted refers to a substitution selected from hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl.

2528. A compound of claim 2427, wherein one of R^1 and R^2 is CF_3 and the other is cyclopropyl.

2629. A compound of claim 2427, wherein one of R^1 and R^2 is CF_3 and the other is CH_2F, or CHF_2.

2730. A compound of claim 2427, wherein both R^1 and R^2 represent cyclopropyl.

~~31. A compound of any of claims 27-30, wherein T is CF or N.~~

~~32. A compound of any of claims 27-31, wherein U, V, W are CH, CF or N.~~

2833. A compound of any of claims 2427-2730, wherein T is CF and U, V, and W are each CH.

2934. A compound of any of claims 2427-2730, wherein T is N and U, V, and W are each CH.

3035. A compound of any of claims 2427-2934, wherein L_1 and L_2 together represent –NH-C(=O)-, C(=O)NH- or $-NH-CH_2-$.


3136. A compound of any of claims 2427-3035, wherein A is absent, -NH-, or $-CH_2-$.

3237. A compound of claim 3136, wherein A is absent.


3338. A compound of claim 3136, wherein A is $-CH_2-$.

3439. A compound of claim 3136, wherein A is –NH-.

3540. A compound of any of claims 2427-3439, wherein Cy is selected from



3641. A compound of claim 3540, wherein Cy is



3742. A compound selected from:

N-[4-(3,5-dicyclopropyl-1*H*-pyrazol-1-yl)phenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide

N-[4-(3,5-dicyclopropyl-1*H*-pyrazol-1-yl)phenyl]-4-methylthiazole-5-carboxamide

N-[4-(3,5-dicyclopropyl-1*H*-pyrazol-1-yl)phenyl]-2,4-dimethylthiazole-5-carboxamide

N-[4-(3,5-dicyclopropyl-1*H*-pyrazol-1-yl)phenyl]-5-methylisoxazole-4-carboxamide

N-[4-(3,5-dicyclopropyl-1*H*-pyrazol-1-yl)phenyl]-3,5-dimethylisoxazole-4-carboxamide

N-[4-(3,5-dicyclopropyl-1*H*-pyrazol-1-yl)phenyl]benzamide

N-[4-(3,5-dicyclopropyl-1*H*-pyrazol-1-yl)phenyl]-2-methylbenzamide

1-{4-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]phenyl}-3-(4-methyl-1,2,3-thiadiazol-5-yl)urea:

1-{4-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]phenyl}-3-(4-methylthiazol-5-yl)urea:

1-{4-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazo-1-yl]phenyl}-3-(4-methylpyrimidin-5-yl)urea:

4-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]-*N*-(4-methylthiazol-5-yl) benzamide:

4-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]-*N*-(2,6-difluorophenyl) benzamide:

N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]phenyl}-4-methylthiazole-5-carboxamide:

N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]phenyl}-2-(pyridin-2-yl)acetamide:

N-{4-[5-(fluoromethyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]phenyl}-4-methylthiazole-5-carboxamide:

N-{4-[5-(difluoromethyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]phenyl}-4-methylthiazole-5-carboxamide:

or a tautomer, ~~prodrug,~~ N-oxide, pharmaceutically acceptable ester, or pharmaceutically acceptable salt thereof.

38~~43~~. A compound selected from:

N-[4-(3,5-dicyclopropyl-1*H*-pyrazol-1-yl)-3-fluorophenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide:

N-[4-(3,5-dicyclopropyl-1*H*-pyrazol-1-yl)-3-fluorophenyl]-4-methylthiazole-5-carboxamide:

N-[4-(3,5-dicyclopropyl-1*H*-pyrazol-1-yl)-3-fluorophenyl]-3,5-dimethylisoxazole-4-carboxamide:

N-[4-(3,5-dicyclopropyl-1*H*-pyrazol-1-yl)-3-fluorophenyl]-2methyl benzamide:

N-[4-(3,5-dicyclopropyl-1*H*-pyrazol-1-yl)-3-fluorophenyl]-2,3-difluorobenzamide:

N-[4-(3,5-dicyclopropyl-1*H*-pyrazol-1-yl)-3-fluorophenyl]-2,6-difluorobenzamide:

N-[4-(3,5-dicyclopropyl-1*H*-pyrazol-1-yl)-3-fluorophenyl]nicotinamide:

N-[4-(3,5-dicyclopropyl-1*H*-pyrazol-1-yl)-3-fluorophenyl]isonicotinamide:

1-{4-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]-3-fluorophenyl}-3-(4-methylpyrimidin-5-yl)urea:

N-{4-[5)-cyclopropyl-3-(trifluromethyl)-1*H*-pyrazol-1-yl]3-flurophenyl}-2,6-dichloro benzamide:

4-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]-*N*-(2,3-difluorophenyl)-3-fluorobenzamide:

4-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]-*N*-(2,6-difluorophenyl)-3-fluorobenzamide:

N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-4-methylpyrimidine-5-carboxamide;

3,5-dichloro-*N*-[4-(3,5-dicyclopropyl-1*H*-pyrazol-1-yl)-3-fluorophenyl]isonicotinamide:

N-(2-chloro-6-fluorophenyl)-4-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]-3-fluorobenzamide:

N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]-3,5-difluorophenyl}-4-methylpyrimidine-5-carboxamide:

{4-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]-3-fluorophenyl}-1-phenylcyclobutanecarboxamide:

N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-4-methyloxazole-5-carboxamide:

4-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]-3-fluoro-*N*-(4-methylpyrimidin-5-yl) benzamide: and

N-{4-[3-cyclopropyl-5-(difluoromethyl)-1*H*-pyrazol-1-yl]-3-fluorophenyl}-2,6-difluorobenzamide and

N-{4-[5-cyclopropyl-3-(difluoromethyl)-1*H*-pyrazol-1-yl]-3-fluorophenyl}-2,6-difluorobenzamide

or a tautomer, ~~prodrug,~~ N-oxide, pharmaceutically acceptable ester, or pharmaceutically acceptable salt thereof.

3944. A compound selected from:

N-[6-(3,5-dicyclopropyl-1*H*-pyrazol-1-yl)pyridin-3-yl]-4-methyl-1,2,3-thiadiazole-5-carboxamide:

N-[6-(3,5-dicyclopropyl-1*H*-pyrazol-1-yl)pyridin-3-yl]-4-methylthiazole-5-carboxamide:

N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]pyridin-3-yl}-2-methylnicotinamide:

N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]pyridin-3-yl}isonicotinamide:

N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide:

3,5-dichloro-*N*-{6-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]pyridin-3-yl}isonicotinamide:

N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]pyridin-3-yl}-4-methylpyrimidine-5-carboxamide:

N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]pyridin-3-yl}-2-(pyridin-2-yl)acetamide;

N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]pyridin-3-yl}-2-(pyridin-4-yl)acetamide;

1-{6-[3-cyclopropyl-5-(trifluoromethyl)-1*H*-pyrazol-1-yl]pyridin-3-yl}-3-(4-methylthiazol-5-yl)urea:

6-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]-*N*-(2,3-difluorophenyl) nicotinamide:

6-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]-*N*-(2,6-difluorophenyl) nicotinamide:

N-{6-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]pyridin-3-yl}-4-methylthiazole-5-carboxamide:


N-{2-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]pyrimidin-5-yl}-2,6-difluorobenzamide:

N-{2-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]pyrimidin-5-yl}-4-methylthiazole-5-carboxamide:

N-{2-[5-cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]pyrimidin-5-yl}-4-methylpyrimidine-5-carboxamide:

or a tautomer, ~~prodrug,~~ N-oxide, pharmaceutically acceptable ester, or pharmaceutically acceptable salt thereof.


4045. A compound of formula



(I)

or a tautomer, ~~prodrug,~~ N-oxide, pharmaceutically acceptable ester or pharmaceutically acceptable salt thereof, wherein

Ring Hy represents




;

optionally substituted with R''';

R^1 and R^2 are the same or different and are independently selected from CH_3, CH_2F, CHF_2, CF_3, substituted or unsubstituted $C_{(3-5)}$cycloalkyl, CH_2-OR^a, CH_2-NR^aR^b, ~~CN~~ and COOH, wherein at least one of R^1 and R^2 is cyclopropyl;

Ring Ar represents:



;

~~T, U, V and W are the same or different and are independently selected from CR^a and N;~~

T is independently selected from CR^a or N and each of U, V and W is independently selected from CH, CR^a or N, wherein each occurrence of R^a is the same or different and are independently selected from nitro, hydroxy, cyano, halogen, -OR^c, -$S(=O)_q$-R^c, –C(=Y)-R^c, -CR^cR^d-C(=Y)-R^c, -CR^cR^d-Y-CR^cR^d-,-C(=Y)-NR^cR^d-, -C(=Y)-NR^cR^d-, -$S(=O)_q$-NR^cR^d-, -NR^cR^d-$S(=O)_q$-NR^cR^d-, -NR^cR^d-NR^cR^d-, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl;

Z^1, Z^2 and Z^3 are the same or different and are independently selected from CR^a, CR^aR^b, O, S and -NR^a, with the proviso that at least one of Z^1, Z^2 and Z^3 represents O, S or -NR^a;

L_1 and L_2 together represent –NH-C(=X)-, –NH-$S(=O)_q$-, -C(=X)NH-, or ~~-S(=O)$_q$NH-~~ or –NH-CR'R''-;

A is absent or selected from –(CR'R'')-, O, $S(=O)_q$, C(=X) and $-NR^a$;

R' and R'' are the same or different and are independently selected from hydrogen, hydroxy, cyano, halogen, $-OR^a$, $-COOR^a$, $-S(=O)_q-R^a$, $-NR^aR^b$, $-C(=X)-R^a$, substituted or unsubstituted $C_{(1-6)}$ alkyl group, substituted or unsubstituted $C_{(1-6)}$ alkenyl, substituted or unsubstituted $C_{(1-6)}$ alkynyl, and substituted or unsubstituted $C_{(3-5)}$ cycloalkyl, or R' and R'' may be joined to form a substituted or unsubstituted saturated or unsaturated 3-6 member

ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR^a and S;

R''' is selected from hydrogen, hydroxy, cyano, halogen, $-OR^a$, $-COOR^a$, $-S(=O)_q-R^a$, $-NR^aR^b$, $-C(=X)-R^a$, substituted or unsubstituted $C_{(1-6)}$ alkyl group, substituted or unsubstituted $C_{(1-6)}$ alkenyl, substituted or unsubstituted $C_{(1-6)}$ alkynyl, and substituted or unsubstituted $C_{(3-5)}$cycloalkyl;

each occurrence of X is independently selected from O, S and $-NR^a$;

Cy is selected from monocyclic substituted or unsubstituted cycloalkyl group, monocyclic substituted or unsubstituted heterocyclyl, monocyclic substituted or unsubstituted aryl, and monocyclic substituted or unsubstituted heteroaryl;

each occurrence of R^a and R^b are the same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, $-OR^c$, $-S(=O)_q-R^c$, $-NR^cR^d$, $-C(=Y)-R^c$, $-CR^cR^d-C(=Y)-R^c$, $-CR^cR^d-Y-CR^cR^d-$,$-C(=Y)-NR^cR^d-$, $-NRR^d-C(=Y)-NR^cR^d-$, $-S(=O)_q-NR^cR^d-$, $-NR^cR^d-S(=O)_q-NR^cR^d-$, $-NR^cR^d-NR^cR^d-$, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocylyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroarylalkyl, or when R^a and R^b are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR^c and S;

each occurrence of R^c and R^d may be same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, or when two R^c and/or R^d substitutents are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which are the same or different and are selected from O, NH and S;

each occurrence of Y is selected from O, S and $-NR^a$; and

each occurrence of q independently represents 0, 1 or 2;

wherein the term substituted refers to a substitution selected from hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (=0), thio(=S), substituted or unsubstituted alkyl,

substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, $-COOR^x$, $-C(0)R^x$, $-C(S)R^X$, $-C(O)ONR^xR^y$, $-NR^yR^z$, $-NR^xCONR^yR^z$, $-N(R^x)SOR^y$, $-N(R^x)S0_2R^y$, $-(=N-N(R^x)R^y)$, $-NR^X$ $C(0)OR^y$, $-NR^xR^y$, $-NR^xC(0)R^y-$, $-R^xC(S)R^y$ $-NR^xC(S)NR^yR^z$, $-SONR^xR^y-$, $-S0_2$ NR^xR^y-, $-OR^x$, $-OR^xC(0)NR^yR^z$, $-OR^xC(0)OR^y-$, $-OC(0)R^x$, $-OC(0)NR^xR^y$, $-R^xNR^yC(0)R^z$, $-R^xOR^y$, $-R^xC(0)OR^y$, $-R^xC(0)NR^yR^z$, $-R^xC(0)R^x$, $-R^xOC(0)R^y$, $-SR^X$, $-SOR^x$, $-S0_2R^x$, and $-ON0_2$, wherein R^x, R^y and R^z in each of the above groups can be hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted heterocyclylalkyl ring, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring, or any two of R^x, R^y and R^z may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include heteroatoms which may be same or different and are selected from O, NR^X or S wherein the substituents in the aforementioned "substituted" groups cannot be further substituted; and wherein

the compound of formula (I) does not include

N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-(difluoromethyl)-5-methyl-1H-Pyrazole-3-carboxamide;

N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-methyl-4-nitro-1H-Pyrazole-5-carboxamide;

N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(1-ethyl-5-methyl-1H-pyrazol-4-yl)-5-Isoxazolecarboxamide;

N-[4-[5-cyclopropyl-3-trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4,5-dihydro-3-(2-methoxyphenyl)-5-isoxazole carboxamide;

N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-[4-(1,1-dimethylethyl)phenyl]-cyclopropanecarboxamide;

N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-3-Pyridinecarboxamide;

N-[4-[3-cyclopropyl-5-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]- 3-Pyridine carboxamide; or

N-benzyl-6-(3,5-dicyclopropyl-1H-pyrazol-1-yl) pyridazin-3-amine.

4146. The compound of claim 4540, wherein R^1 is cyclopropyl.

4247. Use of a compound of any one of claims 1-41 in the manufacture of a medicament for~~A method of~~ modulating store-operated calcium (SOC) channel activity which ~~comprising~~ comprises contacting the SOC channel complex, or portion thereof, with ~~a~~ the compound of any one of claims 1-4641.

4348. Use of a compound of any one of claims 1-41 in the manufacture of a medicament for ~~A method of~~ modulating calcium release activated calcium channel (CRAC) activity in a mammal ~~comprising administering to the mammal a compound of any of claims 1-46~~, wherein the compound of any one of claims 1-~~46~~ 41 modulates CRAC activity in the mammal.

4449. Use of a compound of any one of claims 1-41 in the manufacture of a medicament for ~~A method of~~ inhibiting store-operated calcium entry (SOCE) activation of nuclear factor of activated T cells (NFAT) in a mammal, ~~comprising administering to the mammal a compound of any one of claims 1-46~~ wherein the compound of any one of claims 1-~~46~~ 41 inhibits SOCE activation of NFAT in the mammal.

4550. Use of a compound of any one of claims 1-41 in the manufacture of a medicament for ~~A method of~~ decreasing cytokine release by inhibiting the SOCE activation of NFAT in a mammal ~~comprising administering to the mammal a compound of any one of~~

~~claims 1-46~~, wherein the compound of any one of claims 1-~~46~~ 41 decreases cytokine release in the mammal.

~~51~~46. Use of a compound in any one of claims 1-~~46~~ 41 in the manufacture of a medicament for the treatment of a disease, disorder, or condition that would benefit from modulation of calcium release-activated calcium (CRAC) channel.

~~52~~47. Use of a compound of any one of claims 1-41 in the manufacture of a medicament for ~~A method of~~ inhibiting immune cell activation, wherein the compound of any of claims 1-41 is to be administered ~~comprising administering~~ to an immune cell ~~a compound of any of claims 1-46~~.

~~53~~48. Use of a compound of any one of claims 1-41 in the manufacture of a medicament for ~~A method of~~ inhibiting T-cell and/or B-cell proliferation in response to an antigen~~, comprising administering to a T-cell and/or B-cell cell a compound of any one of claims 1-46~~.

~~54~~49. Use of a compound of any one of claims 1-41 in the manufacture of a medicament for ~~A method of~~ inhibiting cytokine production in a cell~~, comprising administering to the cell a compound of any one of claims 1-46~~.

~~55~~50. The ~~method~~ use of claim ~~54~~49, wherein the cytokine is selected from IL-2, IL-4, IL-5, IL-13, GM-CSF, IFN-γ, TNFα, and combinations thereof.

~~56~~51. Use of a compound of any one of claims 1-41 in the manufacture of a medicament for ~~A method of~~ modulating an ion channel in a cell, wherein the ion channel is involved in immune cell activation~~, comprising administering to the cell a compound of any one of claims 1-46~~.

~~57~~52. The ~~method~~ use of claim ~~56~~51, wherein the ion channel is a Ca^{2+}-release-activated Ca^{2+} channel (CRAC).

~~58~~53. A pharmaceutical composition, comprising a compound of any one of claims 1-~~46~~41 and a pharmaceutically acceptable carrier.

~~59~~54. The pharmaceutical composition of claim ~~58~~53, further comprising one or more additional therapeutic agents selected from anti-inflammatory agent, immunosuppressive agents, steroids, non-steroidal anti-inflammatory agents, antihistamines, analgesics, and suitable mixtures thereof.

55~~60~~. Use of an effective amount of a compound of any one of claims 1-41 in the manufacture of a medicament for ~~A method of~~ treating cancer~~ comprising the step of administering to a subject in need thereof an effective amount of a compound of any one of claims 1-46~~.

56~~61~~. Use of an effective amount of a compound of any one of claims 1-41 in the manufacture of a medicament for ~~A method of~~ reducing an inflammation in a subject in need thereof~~ comprising the step of administering to a subject in need thereof an effective amount of a compound of any one of claims 1-46~~.

57~~62~~. Use of an effective amount of a compound of any one of claims 1-41 in the manufacture of a medicament for ~~A method of~~ treating an autoimmune disorder~~ comprising the step of administering to~~in a subject in need thereof~~ an effective amount of a compound of any one of claims 1-46~~.

58~~63~~. The ~~method~~ use of claim 57~~62~~, wherein the autoimmune disorder is chronic obstructive pulmonary disease, rheumatoid arthritis, inflammatory bowel disease, allergic

rhinitis, asthma, multiple sclerosis, psoriasis, Crohn's disease, colitis, ulcerative colitis, ,arthritis, bone diseases associated with increased bone resorption, or chronic obstructive airway disease.

5964. The ~~method~~ use of claim 5762, wherein the autoimmune disorder is rheumatoid arthritis.

6065. The ~~method~~ use of claim 5762, wherein the autoimmune disorder is multiple sclerosis.

6166. The ~~method~~ use of claim 6257, wherein the autoimmune disorder is asthma~~.~~.

~~67~~62. Use of an effective amount of a compound of any one of claims 1-41 in the manufacture of a medicament ~~A method~~ for the treatment of calcium release-activated calcium (CRAC) channel associated diseases or disorders, ~~comprising the step of administering to~~in a subject in need thereof ~~an effective amount of compound of any one of claims 1-46~~.

6368. A ~~method~~ use of claim 6267, ~~further comprising the step of~~wherein the compound is to be ~~administering~~ administered simultaneously or sequentially to a subject in need thereof in combination with at least one other anti-inflammatory agent, immunosuppressive agent, steroid, non-steroidal anti-inflammatory agent, antihistamine, analgesic, or a mixture thereof.

6469. A ~~method~~ use of claim 6267, wherein the calcium release-activated calcium (CRAC) channel associated disease, disorder or condition is an immune system-related disease, a disease or disorder involving inflammation, a hepatic disease or disorder, or a renal disease or disorder.

6570. A ~~method~~ use of claim 6469, wherein the CRAC channel associated disease, disorder or condition is selected from:

inflammation, glomerulonephritis, uveitis, hepatic diseases or disorders, renal diseases or disorders, chronic obstructive pulmonary disease, rheumatoid arthritis, inflammatory bowel disease, vasculitis, dermatitis, osteoarthritis, inflammatory muscle disease, allergic rhinitis, vaginitis, interstitial cystitis, scleroderma, osteoporosis, eczema, allogeneic or xenogeneic transplantation, graft rejection, graft-versus-host disease, lupus erythematosus, pulmonary fibrosis, dermatomyositis, thyroiditis, myasthenia gravis, autoimmune hemolytic anemia, cystic fibrosis, chronic relapsing hepatitis, primary biliary cirrhosis, allergic conjunctivitis, hepatitis, atopic dermatitis, asthma, Sjogren's syndrome, organ transplant rejection, multiple sclerosis, Guillain-Barre, autoimmune uveitis, autoimmune hemolytic anemia, pernicious anemia, autoimmune thrombocytopenia, temporal arteritis, anti-phospholipid syndrome, vasculitides such as Wegener's granulomatosis, Behcet's disease, psoriasis, dermatitis herpetiformis, pemphigus vulgaris, vitiligo, Crohn's disease, colitis, ulcerative colitis, primary biliary cirrhosis, autoimmune hepatitis, Type 1 or immune-mediated diabetes mellitus, Grave's disease. Hashimoto's thyroiditis, autoimmune oophoritis and orchitis, autoimmune disorder of the adrenal gland, systemic lupus erythematosus, polymyositis, dermatomyositis, ankylosing spondylitis, transplant rejection, skin graft

rejection, arthritis, bone diseases associated with increased bone resorption, ileitis, Barrett's syndrome, adult respiratory distress syndrome, chronic obstructive airway disease, corneal

dystrophy, trachoma, onchocerciasis, sympathetic ophthalmitis, endophthalmitis, gingivitis, periodontitis, tuberculosis, leprosy, uremic complications, nephrosis, sclerodermatitis, psoriasis, chronic demyelinating diseases of the nervous system, AIDS-related neurodegeneration, Alzheimer's disease, infectious meningitis, encephalomyelitis, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis viral or autoimmune encephalitis, autoimmune disorders, immune-complex vasculitis, systemic lupus and erythematodes, systemic lupus erythematosus (SLE), cardiomyopathy, ischemic heart disease hypercholesterolemia, atherosclerosis, preeclampsia; chronic liver failure, brain and spinal cord trauma, and cancer.

6671. Use of an effective amount of a compound of any one of claims 1-41 in the manufacture of a medicament ~~A method~~ for suppressing the immune system of a subject in need thereof~~, comprising administering to the subject an effective amount of a compound of any one of claims 1-46~~.

6772. Use of an effective amount of a compound of any one of claims 1-41 in the manufacture of a medicament ~~A method~~ for treating or preventing an allergic disorder in a subject in need thereof~~, comprising administering to the subject an effective amount of a compound of any one of claims 1-46~~.

6873. The ~~method~~ use of claim 6672, wherein the disorder is allergic rhinitis, sinusitis, rhinosinusitis, chronic otitis media, recurrent otitis media, drug reactions, insect sting reactions, latex reactions, conjunctivitis, urticaria, anaphylaxis reactions, anaphylactoid reactions, atopic dermatitis, asthma, or food allergies.